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Association of a Rheumatoid Arthritis
Susceptibility Variant at the CCL21 Locus With
Premature Mortality in Inﬂammatory Polyarthritis
Patients
TRACEY M. FARRAGHER,1 DARREN PLANT,1 EDWARD FLYNN,1 STEVE EYRE,1 DIANE BUNN,2
WENDY THOMSON,1 DEBORAH SYMMONS,1 AND ANNE BARTON1
Objective. To investigate whether recently identiﬁed rheumatoid arthritis (RA) susceptibility loci are also associated
with disease severity, speciﬁcally all-cause and cardiovascular disease (CVD) mortality, in patients with inﬂammatory
polyarthritis (IP).
Methods. Subjects with recent-onset IP were recruited from the Norfolk Arthritis Register. Seventeen RA susceptibility
single-nucleotide polymorphisms (SNPs) were tested using Sequenom MassArray iPLEX chemistry. Vital status was
ascertained from central records. The association of SNP allele carriage with mortality risk was assessed using Cox
proportional hazards models after adjusting by sex. The mortality risks of those SNP alleles found to be associated were
then stratiﬁed by baseline anti–citrullinated peptide (anti-CCP) antibody and shared epitope (SE) status.
Results. All SNPs were successfully genotyped in 2,324 IP subjects. The presence of 2 copies of the risk allele rs2812378
mapping to the CCL21 gene predicted all-cause mortality (hazard ratio [HR] 1.40, 95% conﬁdence interval [95% CI]
1.04–1.87), whereas risk allele carriage also predicted increased CVD mortality (HR 1.33, 95% CI 1.01–1.75). The highest
mortality risks were seen in anti-CCP antibody–positive subjects with 2 copies of the CCL21 risk alleles and 2 copies of
the SE (all-cause HR 3.20, 95% CI 1.52–6.72; CVD HR 3.73, 95% CI 1.30–10.72).
Conclusion. In this large study, we found that carriage of CCL21 risk alleles was associated with premature mortality in
IP independently of anti-CCP antibody and SE status. Interestingly, CCL21 expression has been reported in atherosclerotic
plaques supporting the thesis that the increased CVD mortality in IP patients may be mediated by shared inﬂammatory
mechanisms.
INTRODUCTION
With better long-term control of disease activity now pos-
sible in patients with rheumatoid arthritis (RA) due to the
earlier, more aggressive use of disease-modifying antirheu-
matic drugs and the advent of biologic therapies, interest is
now focusing on preventing the comorbidities that occur
more commonly in this condition. Patients with RA die
prematurely, often from cardiovascular disease (CVD) (1).
However, traditional CVD risk factors, such as smoking
and dyslipidemia, do not appear to account for all of the
excess risk (2). Because there is evidence for an inﬂamma-
tory component in both RA and CVD, we hypothesized
that shared genetic risk factors may account for the excess
prevalence of CVD in RA.
We have previously reported that the major RA suscep-
tibility locus, the group of HLA–DRB1 alleles collectively
referred to as the shared epitope (SE), is associated with
both all-cause and CVD mortality in patients with inﬂam-
matory polyarthritis (IP) and RA, but that the second-
strongest susceptibility gene, PTPN22, shows no such as-
sociation (3). Over the last 2 years, there has been
considerable progress in identifying further RA suscepti-
bility genes, and at least 11 other loci have been reported
to be associated with RA in more than one well-powered
study (4–12). Many of these susceptibility genes are in-
Supported by the Arthritis Research Campaign, UK (arc
grant reference 17552).
1Tracey M. Farragher, PhD, Darren Plant, PhD, Edward
Flynn, BSc, Steve Eyre, PhD, Wendy Thomson, PhD, Debo-
rah Symmons, MD, FRCP, Anne Barton, PhD, FRCP: arc Ep-
idemiology Unit, The University of Manchester, Manches-
ter, UK; 2Diane Bunn, MSc: Norfolk Arthritis Register,
University of East Anglia, Norwich, UK.
Address correspondence to Anne Barton, PhD, FRCP,
arc Epidemiology Unit, The University of Manchester,
Manchester Academic Health Science Centre, Stopford
Building, Oxford Road, Manchester, M13 9PT UK. E-mail:
anne.barton@manchester.ac.uk.
Submitted for publication August 10, 2009; accepted in
revised form January 15, 2010.
Arthritis Care & Research
Vol. 62, No. 5, May 2010, pp 676–682
DOI 10.1002/acr.20208
© 2010, American College of Rheumatology
ORIGINAL ARTICLE
676
volved in immune regulation and inﬂammation, and many
show overlap with other complex immune/inﬂammatory
diseases. For example, single-nucleotide polymorphism
(SNP) markers mapping to a region on chromosome 9
encompassing the TRAF1 and part of the C5 genes, which
have been widely conﬁrmed as being associated with RA
susceptibility, were reported to be associated with CVD
mortality in a small, hospital-based series of RA patients
(13). The aim of the current study was to investigate
whether the recently identiﬁed RA susceptibility loci are
also associated with all-cause mortality, and speciﬁcally
CVD mortality, in an inception cohort of patients with IP
followed prospectively.
PATIENTS AND METHODS
Study design. A cohort analysis was undertaken com-
paring survival in subjects with IP according to RA sus-
ceptibility SNP marker genotype.
Subjects. Subjects were recruited from the Norfolk Ar-
thritis Register (NOAR), a primary care–based inception
cohort of subjects with recent-onset IP that has been de-
scribed previously (14). Brieﬂy, from 1989 onward, the
NOAR aimed to recruit all adults age 16 years who had
swelling of at least 2 joints persisting for at least 4 weeks.
The NOAR covers the former Norwich Health Authority
with notiﬁcation of cases via general practitioners or at-
tendance at hospitals within the catchment area (14).
Those who were subsequently diagnosed by a hospital
consultant as having a condition other than RA, IP, psori-
atic arthritis, or postviral arthritis were excluded. Between
1989 and 2005, 2,469 consecutive subjects who satisﬁed
the above criteria and had a DNA sample available for
genotyping were referred to the NOAR. All of the subjects
were white.
Data collection. A research nurse conducted a struc-
tured interview and clinical examination at baseline. De-
mographic data collected included the age at symptom
onset, sex, smoking status, and time from symptom onset
to presentation to the NOAR. A blood sample was tested
for rheumatoid factor (RF), anti–cyclic citrullinated pep-
tide (anti-CCP) antibody, and C-reactive protein level. RF
was measured using a latex agglutination technique,
where a titer of 1:40 was classiﬁed as RF positive. Anti-
CCP antibodies were detected using the Axis-Shield DI-
ASTAT kit according to the manufacturer’s instructions,
where a concentration of 5 units/ml was classiﬁed as
anti-CCP antibody positive (Axis-Shield). The American
College of Rheumatology (ACR; formerly the American
Rheumatism Association) 1987 criteria (15) for the classi-
ﬁcation of RA were applied at baseline.
Genotyping. Seventeen SNPs were selected for genotyp-
ing and tested using Sequenom MassArray iPLEX chemis-
try according to the manufacturer’s instructions (online at:
http://www.sequenom.com). The SNPs were markers as-
sociated with RA susceptibility in cohorts tested by our
group and others, and consisted of: rs1160542 (AFF3);
rs2812378 (CCL21); rs763361 (CD226); rs4810485 (CD40);
rs3087243 and rs231775 (CTLA4); rs6822844 (IL2/IL21);
rs2104286 (IL2RA); rs743777 (IL2RB); rs6897932 (IL7R);
rs1678542 (KIF5A); rs7574865 (STAT4); rs13207033,
rs5029937, and rs6920220 (OILG3/TNFAIP3); and
rs10760130 and rs2900180 (TRAF1/C5). Only those SNPs
with a genotype success rate of 85% were included in
the analysis. HLA genotyping was performed as described
previously (16).
Ascertainment of deaths. Death was ascertained by
record linkage with the UK Ofﬁce for National Statistics
(ONS). The cause of death was coded using the Interna-
tional Statistical Classiﬁcation of Diseases and Related
Health Problems, Tenth Revision (ICD-10) (17). Cause of
death was grouped by ICD-10 chapter. Patients were fol-
lowed from disease symptom onset until death or Decem-
ber 31, 2007, whichever was sooner. The ONS notiﬁed the
NOAR if a patient moved from the UK or was no longer
registered with a general practitioner, giving a date of
embarkation. For these subjects, followup was censored to
the time of embarkation.
Statistical analysis. The association of SNP marker al-
lele carriage with mortality risk was assessed using Cox
proportional hazards models after adjusting by sex. Each
subject entered the analysis on their date of birth and
became at risk of mortality on the date of symptom onset.
Analyses were undertaken for all-cause and CVD mortal-
ity, which we deﬁned as any mention of CVD (ICD-10
codes I00–I99) on the death certiﬁcate. This analysis was
carried out on the IP cohort and the subgroup that satisﬁed
the ACR criteria for RA by the end of 2007 or death,
whichever was sooner.
Because smoking is a known risk factor for CVD, analy-
sis of the SNPs with evidence for association with all-
cause or CVD mortality was repeated after adjusting for
baseline smoking status (current/ever/never) to determine
whether smoking was an important confounding factor.
We have previously found anti-CCP antibody status, a
marker of disease severity, and carriage of 2 copies of SE
alleles to be predictors of mortality (3). For any SNP asso-
ciated with mortality in the current study, interaction ana-
lysis with SE status (0/1 versus 2 SE alleles) and anti-CCP
antibody status was assessed via Cox proportional hazards
models after adjusting by sex. All analyses were under-
taken using Stata, version 9.2 (StataCorp).
RESULTS
After applying strict quality control measures, all 17 SNPs
were successfully genotyped in 2,324 IP subjects. Of the
2,324 IP subjects, 1,027 (44.2%) satisﬁed the ACR criteria
for RA at baseline (Table 1). By December 31, 2007, 399
subjects (17.2%) had died and CVD was recorded on the
death certiﬁcate for 216 subjects (54% of all deaths).
RA susceptibility alleles as predictors of all-cause and
CVD mortality. In order to conﬁrm that the data set used
in the current analysis was comparable with RA cohorts
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tested previously to investigate susceptibility loci, we ﬁrst
compared allele frequencies in the IP subjects with 875 UK
controls for whom genotyping data were available for the
same SNPs. The odds ratios in the current IP cohort were
similar (same direction and magnitude) to those found in
the larger RA case–control cohorts reported previously,
although as expected due to the smaller sample size, these
associations were only statistically signiﬁcant for 3 of the
variants (Supplementary Table 1, available in the online
version of this article at http://www3.interscience.
wiley.com/journal/77005015/home).
Only 1 SNP was associated with all-cause mortality
(Table 2) in the IP cohort. Carriage of 2 copies of the risk
allele of rs2812378 mapping to the CCL21 gene was asso-
ciated with a signiﬁcantly increased risk of all-cause mor-
tality compared with carriage of 2 copies of the non–risk
allele (hazard ratio [HR] adjusted by sex 1.40, 95% conﬁ-
dence interval [95% CI] 1.04–1.87). Carriage of this risk
allele was also associated with CVD mortality compared
with those who were homozygous for the non–risk allele
(HR adjusted by sex 1.33, 95% CI 1.01–1.75) (Table 3). No
association was found with either all-cause or CVD mor-
tality and carriage of the risk alleles for any other loci
(Supplementary Tables 2 and 3, available in the online
version of this article at http://www3.interscience.wiley.
com/journal/77005015/home), including SNPs rs10760130
and rs2900180 mapping to the TRAF1/C5 locus, which
were previously reported to be associated with CVD mor-
tality (Tables 2 and 3). No statistically signiﬁcant associa-
tions were found for either all-cause or CVD mortality with
the RA susceptibility alleles in the RA subgroup, although
the estimates for the mortality risk are similar to those
from the entire IP cohort.
To explore whether the increased mortality risk was as a
result of traditional CVD risk factors, we adjusted the HRs
in Tables 2 and 3 by smoking status at baseline (never,
previous, current). We found very little change in the
estimates for mortality risk in the selected susceptibility
SNP loci. In particular, carriage of 2 copies of the risk
allele rs2812378 mapping to the CCL21 gene remained
associated with a signiﬁcantly increased risk of all-cause
mortality (HR adjusted by sex and smoking 1.38, 95% CI
1.02–1.87) and CVD mortality (HR adjusted by sex and
smoking 1.66, 95% CI 1.11–2.48) compared with those
who were homozygous for the non–risk allele. Further-
more, carriage of this risk allele remained associated with
CVD mortality compared with those who were homozy-
gous for the non–risk allele (HR adjusted by sex and smok-
ing 1.37, 95% CI 1.03–1.81). No association was found
with either all-cause or CVD mortality or carriage of the
risk alleles for any other loci after adjustment for smoking
and sex.
CCL21 risk allele as a predictor of mortality by baseline
anti-CCP antibody status. Carriage of 2 copies of the
CCL21 risk allele was associated with increased all-cause
mortality in patients who were anti-CCP antibody negative
(HR 1.48, 95% CI 1.00–2.20), but was stronger in those
who were anti-CCP antibody positive (HR for 2 copies
versus 0 copies of risk allele 1.97, 95% CI 1.21–3.21)
(Table 4). Increased risk of CVD mortality and carriage of
the CCL21 risk allele was also seen in those who were
anti-CCP antibody negative, although it did not reach sta-
tistical signiﬁcance (HR for 1 or 2 copies versus 0 copies
1.45, 95% CI 0.99–2.12), and was higher in those who
were anti-CCP antibody positive (HR 2.36, 95% CI 1.54–
3.61). Stratiﬁcation analysis of the other RA susceptibility
alleles by anti-CCP antibody status revealed no additional
mortality risk in anti-CCP antibody–positive or –negative
subgroups (data not shown).
CCL21 risk allele as a predictor of mortality by SE
status. The association of carriage of the CCL21 risk allele
with increased CVD mortality was independent of SE sta-
tus (HR in those with 0 or 1 copy of the SE 1.44, 95% CI
1.03–2.03; HR in those with 2 copies of the SE 1.87, 95%
CI 1.14–3.06) (Table 5). The increased all-cause mortality
risk in those with 2 copies of the CCL21 risk allele was
only seen in those with 2 copies of the SE (HR 2.67, 95%
CI 1.43–5.00).
Interaction of SE, anti-CCP antibody, and CCL21 risk
allele as predictors of mortality. Using a multiplicative
model, subjects with 2 copies of the CCL21 risk allele and
2 copies of the SE and who were anti-CCP antibody posi-
Table 1. Clinical and demographic characteristics of the
entire IP cohort*
IP cohort
(n  2,324)
Age at symptom onset,
median (IQR) years
54 (42–66)
Delay to registration,
median (IQR) months
7 (3–14)
CRP level (n  1,985),
median (IQR) mg/dl
7.7 (1.5–18.3)
Women 1,537 (66.1)
Satisfy ACR criteria for RA at
baseline
1,027 (44.2)
RF positive at baseline
(n  2,169)†
690 (31.8)
Anti-CCP antibody positive
at baseline (n  2,046)
624 (30.5)
Copies of SE alleles
(n  1,567)
0/1 1,373 (87.6)
2 194 (12.4)
Smoking status at baseline
(n  2,010)
Never smoked 524 (26.1)
Ex-smoker 911 (45.3)
Current smoker 575 (28.6)
Died by the end of 2007 399 (17.2)
Died (CVD) by the end of
2007
229 (9.9)
* Values are the number (percentage) unless otherwise indicated.
IP  inﬂammatory polyarthritis; IQR  interquartile range; CRP 
C-reactive protein; ACR  American College of Rheumatology;
RA  rheumatoid arthritis; RF  rheumatoid factor; anti-CCP 
anti–cyclic citrullinated peptide; SE  shared epitope; CVD 
cardiovascular disease.
† Titer 1:40.
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tive had a signiﬁcantly higher all-cause mortality (HR 3.20,
95% CI 1.52–6.72) and CVD mortality (HR 3.73 95% CI
1.30–10.72) when compared with those who were anti-
CCP antibody negative who had 0 or 1 copy of the SE and
0 copies of the CCL21 risk allele (Table 6). When using an
additive model to estimate the mortality associated with
the combination of these 3 risk factors, we found lower
HRs (all-cause HRs 1.99, 1.20, and 3.32; CVD HRs 2.98,
1.53, and 5.80). This indicates that there is an interaction
between the 2 genetic markers and anti-CCP antibody sta-
tus rather than just an additive effect on the mortality risk.
DISCUSSION
To our knowledge, this is the ﬁrst study to explore the
association of those SNPs that have recently been identi-
ﬁed as RA susceptibility loci with all-cause and CVD mor-
tality in subjects with IP. Carriage of 1 or more risk alleles
of rs2812378 mapping to the CCL21 gene was associated
with increased CVDmortality, whereas carriage of 2 copies
of the risk allele was associated with increased all-cause
mortality. These effects on mortality were independent of
anti-CCP antibody and SE status.
The CCL21 gene is one of several Cys-Cys cytokine genes
clustered on the short arm of chromosome 9. The CCL21
protein is a chemokine that is involved in homing lym-
phocytes to secondary lymphoid organs. Expression of this
chemokine is associated with ectopic lymphoid structures
and has been implicated in the organization of lymphoid
tissue affected by RA (18). Furthermore, the CCL21 mole-
cule and its receptor CCR7 have a possible role in the
development of atherosclerosis by recruiting T cells and
macrophages to the atherosclerotic lesions and by promot-
ing inﬂammatory responses in these cells (19,20). The
association between the risk allele at this gene and mor-
tality, particularly CVD mortality, in RA highlights the
potential that the excess CVD mortality observed in pa-
tients with RA may be related to abnormalities in the
inﬂammatory process (1).
The size of the cohort gave us the potential to explore
the effect of a combination of genetic predictors on mor-
tality. The failure of SE status (0/1 versus 2) to explain the
Table 2. All-cause mortality at the end of 2007 by selected RA susceptibility SNP loci*
No.
Unadjusted,
HR (95% CI)
Adjusted by sex,
HR (95% CI)
Inﬂammatory polyarthritis
rs2900180
0 risk alleles 902 1.0 1.0
1 risk allele 1,052 1.09 (0.88–1.36) 1.1 (0.88–1.36)
1/2 risk alleles 1.06 (0.87–1.31) 1.07 (0.87–1.31)
2 risk alleles 343 0.98 (0.73–1.34) 0.99 (0.73–1.34)
rs10760130
0 risk alleles 673 1.0 1.0
1 risk allele 1,118 0.98 (0.77–1.23) 0.98 (0.78–1.24)
1/2 risk alleles 1.01 (0.81–1.26) 1.02 (0.82–1.27)
2 risk alleles 510 1.10 (0.83–1.44) 1.10 (0.84–1.45)
rs2812378
0 risk alleles 954 1.0 1.0
1 risk allele 1,072 0.97 (0.78–1.20) 0.98 (0.79–1.22)
1/2 risk alleles 1.05 (0.86–1.29) 1.07 (0.87–1.30)
2 risk alleles 274 1.37 (1.03–1.84)† 1.40 (1.04–1.87)†
RA subgroup (met ACR criteria for RA by
the end of 2007)
rs2900180
0 risk alleles 609 1.0 1.0
1 risk allele 731 1.24 (0.96–1.60) 1.25 (0.97–1.61)
1/2 risk alleles 1.18 (0.93–1.51) 1.19 (0.93–1.51)
2 risk alleles 236 1.01 (0.70–1.45) 1.01 (0.70–1.45)
rs10760130
0 risk alleles 454 1.0 1.0
1 risk allele 780 1.07 (0.81–1.40) 1.07 (0.81–1.41)
1/2 risk alleles 1.06 (0.82–1.38) 1.07 (0.82–1.38)
2 risk alleles 344 1.05 (0.76–1.47) 1.06 (0.76–1.48)
rs2812378
0 risk alleles 661 1.0 1.0
1 risk allele 725 0.94 (0.73–1.21) 0.94 (0.73–1.22)
1/2 risk alleles 0.99 (0.79–1.26) 1.00 (0.79–1.27)
2 risk alleles 191 1.18 (0.84–1.67) 1.20 (0.85–1.69)
* RA rheumatoid arthritis; SNP single-nucleotide polymorphism; HR hazard ratio; 95% CI 95% conﬁdence interval; ACRAmerican College
of Rheumatology.
† P  0.05.
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elevated CVD mortality risk of patients with risk alleles at
the CCL21 locus may indicate an independent effect to that
which we have previously found for the SE (3). We were
unable to replicate the recently found association between
SNP markers mapping to TRAF1/C5 and CVD mortality
(13). Because we had more than 90% power to detect
statistically signiﬁcant effects, for the mortality risks esti-
mated for the 2 TRAF1/C5 SNPs, rs10760130 and
rs2900180, from the previous report, our results are un-
likely to represent false-negative ﬁndings. However, there
Table 3. CVD mortality at the end of 2007 by selected RA susceptibility SNP loci*
No.
Unadjusted,
HR (95% CI)
Adjusted by sex,
HR (95% CI)
Inﬂammatory polyarthritis
rs2900180
0 risk alleles 902 1.0 1.0
1 risk allele 1,052 1.14 (0.86–1.51) 1.14 (0.86–1.52)
1/2 risk alleles 1.05 (0.80–1.37) 1.05 (0.80–1.38)
2 risk alleles 343 0.79 (0.51–1.21) 0.80 (0.52–1.23)
rs10760130
0 risk alleles 673 1.0 1.0
1 risk allele 1,118 0.99 (0.73–1.33) 0.99 (0.74–1.35)
1/2 risk alleles 0.95 (0.72–1.27) 0.96 (0.72–1.28)
2 risk alleles 510 0.88 (0.60–1.28) 0.89 (0.61–1.30)
rs2812378
0 risk alleles 954 1.0 1.0
1 risk allele 1,072 1.23 (0.92–1.64) 1.25 (0.93–1.67)
1/2 risk alleles 1.31 (0.99–1.72) 1.33 (1.01–1.75)†
2 risk alleles 274 1.60 (1.08–2.35)† 1.63 (1.11–2.41)†
RA subgroup (met ACR criteria for RA by
the end of 2007)
rs2900180
0 risk alleles 609 1.0 1.0
1 risk allele 731 1.26 (0.91–1.74) 1.28 (0.92–1.76)
1/2 risk alleles 1.10 (0.81–1.51) 1.12 (0.82–1.53)
2 risk alleles 236 0.67 (0.39–1.15) 0.68 (0.40–1.16)
rs10760130
0 risk alleles 454 1.0 1.0
1 risk allele 780 1.08 (0.77–1.53) 1.09 (0.77–1.54)
1/2 risk alleles 0.97 (0.70–1.36) 0.99 (0.71–1.38)
2 risk alleles 344 0.74 (0.46–1.17) 0.76 (0.48–1.20)
rs2812378
0 risk alleles 661 1.0 1.0
1 risk allele 725 1.08 (0.78–1.51) 1.11 (0.80–1.55)
1/2 risk alleles 1.15 (0.84–1.56) 1.18 (0.87–1.61)
2 risk alleles 191 1.35 (0.87–2.10) 1.41 (0.91–2.19)
* CVD  cardiovascular disease; RA  rheumatoid arthritis; SNP  single-nucleotide polymorphism; HR  hazard ratio; 95% CI  95% conﬁdence
interval; ACR  American College of Rheumatology.
† P  0.05.
Table 4. All-cause and CVD mortality (adjusted by sex) by RA susceptibility, SNP locus, and anti-CCP antibody status*
All-cause mortality/
anti-CCP antibody
negative
All-cause mortality/
anti-CCP antibody
positive
CVD mortality/anti-CCP
antibody negative
CVD mortality/anti-
CCP antibody positive
No. HR (95% CI) No. HR (95% CI) No. HR (95% CI) No. HR (95% CI)
rs2812378
0 risk alleles 583 1.0 262 1.52 (1.07–2.15) 583 1.0 262 2.18 (1.36–3.49)
1 risk allele 664 0.96 (0.72–1.29) 278 1.51 (1.08–2.13) 664 1.38 (0.93–2.06) 278 2.27 (1.44–3.58)
2 risk alleles 159 1.48 (1.00–2.20) 78 1.97 (1.21–3.21) 159 1.72 (0.98–3.01) 78 2.70 (1.41–5.16)
1/2 risk alleles 823 1.06 (0.81–1.39) 356 1.62 (1.18–2.21) 823 1.45 (0.99–2.12) 356 2.36 (1.54–3.61)
* CVD  cardiovascular disease; RA  rheumatoid arthritis; SNP  single-nucleotide polymorphism; anti-CCP  anti–cyclic citrullinated peptide;
HR  hazard ratio; 95% CI  95% conﬁdence interval.
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are differences in the types of patients studied (hospital
RA rather than primary care–based IP), which may explain
the lack of association that we observed.
Because this study used a primary care–based cohort of
subjects with IP, it had limited selection bias. Further-
more, the sample size was large and subjects had long
followup, and therefore we were able to produce robust
estimates of the inﬂuence of selected SNP markers on
mortality. However, we cannot rule out the possibility of a
false-positive ﬁnding at the CCL21 locus because no ad-
justment was made for multiple testing. The ﬁnding will
need to be replicated in other cohorts before the SNP can
be considered as a conﬁrmed predictor of all-cause and
CVD mortality.
A potential limitation of the current study could be the
exclusion of subjects from the analysis, either because they
did not provide a DNA sample (n  1,264) or were lost to
followup by the ONS (n  23), if these individuals were
systematically different from the subjects included in the
study. However, no systematic differences in clinical char-
acteristics were detected (data not shown). The initial ana-
lysis was undertaken in the IP cohort as a whole and in the
subgroup satisfying the ACR criteria for RA. We did not
ﬁnd signiﬁcant associations with any of the RA suscepti-
bility alleles and mortality in the RA subgroup. However,
there was little difference in the estimates for the RA
subgroup compared with the entire IP cohort, and there-
fore the lack of signiﬁcant ﬁndings could be a result of the
smaller sample size. It might be argued that we should
have also investigated the mortality risk for the RA sus-
Table 5. All-cause and CVD mortality (adjusted by sex) by RA susceptibility, SNP locus, and SE*
All-cause mortality/0/1
copy of SE alleles
All-cause mortality/2
copies of SE alleles
CVD mortality/0/1 copy
of SE alleles
CVD mortality/2 copies
of SE alleles
No. HR (95% CI) No. HR (95% CI) No. HR (95% CI) No. HR (95% CI)
rs2812378
0 risk alleles 613 1.0 98 1.54 (0.95–2.50) 613 1.0 98 1.69 (0.85–3.36)
1 risk allele 695 1.08 (0.83–1.41) 128 0.98 (0.62–1.57) 695 1.43 (1.00–2.05) 128 1.63 (0.94–2.83)
2 risk alleles 178 1.24 (0.86–1.79) 36 2.67 (1.43–5.00) 178 1.50 (0.91–2.47) 36 3.21 (1.37–7.54)
1/2 risk alleles 873 1.12 (0.87–1.43) 164 1.26 (0.84–1.87) 873 1.44 (1.03–2.03) 164 1.87 (1.14–3.06)
* CVD  cardiovascular disease; RA  rheumatoid arthritis; SNP  single-nucleotide polymorphism; SE  shared epitope; HR  hazard ratio; 95%
CI  95% conﬁdence interval.
Table 6. All-cause and CVD mortality (adjusted by sex) at the end of 2007 by RA susceptibility, SNP locus, SE, and anti-CCP
antibody status*
All-cause mortality/0/1
copy of SE alleles
All-cause mortality/2
copies of SE alleles
CVD mortality/0/1 copy
of SE alleles
CVD mortality/2
copies of SE alleles
No. HR (95% CI) No. HR (95% CI) No. HR (95% CI) No. HR (95% CI)
Anti-CCP antibody
negative
rs2812378
0 risk alleles 387 1.0 28 1.62 (0.59–4.49) 387 1.0 28 –†
1 risk allele 430 1.10 (0.78–1.54) 48 0.59 (0.24–1.47) 430 1.56 (0.98–2.49) 48 0.97 (0.34–2.75)
2 risk alleles 112 1.39 (0.87–2.22) 7 1.06 (0.15–7.71) 112 1.50 (0.76–2.95) 7 2.43 (0.33–17.98)
Anti-CCP antibody
positive
rs2812378
0 risk alleles 154 1.47 (0.95–2.29) 56 1.90 (1.04–3.48) 154 1.91 (1.04–3.49) 56 3.15 (1.48–6.72)
1 risk allele 178 1.63 (1.08–2.45) 56 1.34 (0.69–2.62) 178 2.02 (1.15–3.57) 56 3.50 (1.78–6.89)
2 risk alleles 41 1.40 (0.67–2.93) 24 3.20 (1.52–6.72) 41 1.90 (0.73–4.92) 24 3.73 (1.30–10.72)
Anti-CCP antibody
negative
rs2812378
0 risk alleles 387 1.0 28 1.62 (0.59–4.49) 387 1.0 28 –†
1/2 risk alleles 542 1.16 (0.84–1.60) 55 0.64 (0.28–1.48) 542 1.55 (0.99–2.42) 55 1.10 (0.42–2.84)
Anti-CCP antibody
positive
rs2812378
0 risk alleles 154 1.47 (0.95–2.28) 56 1.90 (1.04–3.47) 154 1.90 (1.04–3.49) 56 3.14 (1.47–6.70)
1/2 risk alleles 219 1.58 (1.08–2.33) 80 1.80 (1.06–3.06) 219 2.00 (1.17–3.41) 80 3.55 (1.92–6.57)
* CVD  cardiovascular disease; RA  rheumatoid arthritis; SNP  single-nucleotide polymorphism; SE  shared epitope; anti-CCP  anti–cyclic
citrullinated peptide; HR  hazard ratio; 95% CI  95% conﬁdence interval.
† Too few events to calculate robust estimates.
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ceptibility alleles in the RF-positive individuals, particu-
larly because we have previously found that RF positivity
is a predictor of mortality (3,21). However, in this cohort,
we found that anti-CCP antibodies were a stronger predic-
tor of mortality than RF. Compared with those negative for
both RF and anti-CCP antibodies, those anti-CCP antibody
positive and RF negative had an increased mortality risk
(all-cause HR 2.24, 95% CI 1.46–3.43), whereas those RF
positive and anti-CCP antibody negative did not have an
increased mortality risk (all-cause HR 0.90, 95% CI 0.50–
1.60).
Although we have found evidence that a marker associ-
ated with RA susceptibility may contribute to CVD mor-
tality, the combination of anti-CCP antibodies, CCL21, and
SE status does not explain all of the increased risk. Fur-
thermore, even with the large sample size, we had rela-
tively few cases with the combination of the 3 risk factors.
A well-powered, unbiased, genome-wide association
study has greater potential to identify further markers of
CVD in RA compared with candidate gene studies, and
may be required to ﬁnd additional genetic risk factors that
predict outcome. Identiﬁcation of such markers would be
an important clinical advance because it could allow bet-
ter targeting of preventative therapies (e.g., lifestyle mod-
iﬁcation, aggressive treatment) to those patients with IP
who are at high risk of premature mortality from CVD.
ACKNOWLEDGEMENTS
We would like to acknowledge the contribution of the
local general practitioners and rheumatologists in referring
patients to the register, the NOAR metrologists in the col-
lection of the clinical data, and database manager
Stephanie Manning. We also acknowledge the support of
the National Institute for Health Research Manchester Bio-
medical Research Centre.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors ap-
proved the ﬁnal version to be submitted for publication. Dr. Bar-
ton had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the
data analysis.
Study conception and design. Farragher, Plant, Flynn, Thomson,
Symmons, Barton.
Acquisition of data. Plant, Flynn, Eyre, Bunn, Symmons.
Analysis and interpretation of data. Farragher, Thomson.
REFERENCES
1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Es-
daile JM, Lacaille D. Risk of cardiovascular mortality in pa-
tients with rheumatoid arthritis: a meta-analysis of observa-
tional studies. Arthritis Rheum 2008;59:1690–7.
2. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV,
Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary
heart disease and sudden deaths in rheumatoid arthritis: a
population-based cohort study. Arthritis Rheum 2005;52:
402–11.
3. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson
W, Symmons D, et al. Association of the HLA–DRB1 gene
with premature death, particularly from cardiovascular dis-
ease, in patients with rheumatoid arthritis and inﬂammatory
polyarthritis. Arthritis Rheum 2008;58:359–69.
4. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, et al.
Rheumatoid arthritis association at 6q23. Nat Genet 2007;39:
1431–3.
5. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, et al.
Re-evaluation of putative rheumatoid arthritis susceptibility
genes in the post-genome wide association study era and
hypothesis of a key pathway underlying susceptibility. Hum
Mol Genet 2008;17:2274–9.
6. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, et al.
Rheumatoid arthritis susceptibility loci at chromosomes
10p15, 12q13 and 22q13. Nat Genet 2008;40:1156–9.
7. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C,
Burtt NP, et al. Common variants at CD40 and other loci
confer risk of rheumatoid arthritis. Nat Genet 2008;40:1216–
23.
8. Haﬂer JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Sim-
monds MJ, et al. CD226 Gly307Ser association with multiple
autoimmune diseases. Genes Immun 2009;10:5–10.
9. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI,
Maller J, et al. Two independent alleles at 6q23 associated
with risk of rheumatoid arthritis. Nat Genet 2007;39:1477–82.
10. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF,
Ding B, et al. TRAF1–C5 as a risk locus for rheumatoid
arthritis: a genomewide study. N Engl J Med 2007;357:1199–
209.
11. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Beh-
rens TW, et al. STAT4 and the risk of rheumatoid arthritis and
systemic lupus erythematosus. N Engl J Med 2007;357:977–
86.
12. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA,
Coenen MJ, Franke B, et al. Novel association in chromosome
4q27 region with rheumatoid arthritis and conﬁrmation of
type 1 diabetes point to a general risk locus for autoimmune
diseases. Am J Hum Genet 2007;81:1284–8.
13. Panoulas VF, Smith JP, Nightingale P, Kitas GD. Association
of the TRAF1/C5 locus with increased mortality, particularly
from malignancy or sepsis, in patients with rheumatoid ar-
thritis. Arthritis Rheum 2009;60:39–46.
14. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ.
The incidence of rheumatoid arthritis in the United Kingdom:
results from the Norfolk Arthritis Register. Br J Rheumatol
1994;33:735–9.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association
1987 revised criteria for the classiﬁcation of rheumatoid ar-
thritis. Arthritis Rheum 1988;31:315–24.
16. Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett
J, et al. Quantifying the exact role of HLA–DRB1 alleles in
susceptibility to inﬂammatory polyarthritis: results from a
large, population-based study. Arthritis Rheum 1999;42:757–
62.
17. World Health Organization. International classiﬁcation of dis-
eases, tenth revision. Geneva: WHO; 1994.
18. Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni
G, et al. Systematic microanatomical analysis of CXCL13 and
CCL21 in situ production and progressive lymphoid organi-
zation in rheumatoid synovitis. Eur J Immunol 2005;35:1347–
59.
19. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, Waehre T,
et al. Enhanced expression of the homeostatic chemokines
CCL19 and CCL21 in clinical and experimental
atherosclerosis: possible pathogenic role in plaque destabili-
zation. Arterioscler Thromb Vasc Biol 2007;27:614–20.
20. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, et
al. Gene expression changes in foam cells and the role of
chemokine receptor CCR7 during atherosclerosis regression
in ApoE-deﬁcient mice. Proc Natl Acad Sci U S A 2006;103:
3781–6.
21. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Sym-
mons DP. Mortality in early inﬂammatory polyarthritis: car-
diovascular mortality is increased in seropositive patients.
Arthritis Rheum 2002;46:2010–9.
682 Farragher et al
